Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling

Oncogene

Volumn 29, Issue 1, 2010, Pages 139-149

  Yalcin, A ^a,b   Clem, B ^a   Makoni, S ^a   Clem, A ^a   Nelson, K ^a   Thornburg, J ^a   Siow, D ^a   Lane, A N ^a   Brock, S E ^a   Goswami, U ^a   Eaton, J W ^a   Telang, S ^a   Chesney, J ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b ULUDAG UNIVERSITY   (Turkey)

Author keywords

Phosphatidic acid; Phosphocholine; Ras

Indexed keywords

CHOLINE KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE D2; PHOSPHORYLCHOLINE; PROTEIN KINASE B; SMALL INTERFERING RNA;

ARTICLE; ATTENUATION; BRONCHUS MUCOSA; CANCER SURVIVAL; CELL ANCHORAGE; CELL IMMORTALIZATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM CELL; GENE AMPLIFICATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; ONCOGENE H RAS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BLOTTING, WESTERN; CELL LINE, TRANSFORMED; CHOLINE KINASE; FEMALE; HELA CELLS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS, EXPERIMENTAL; PHOSPHATIDIC ACIDS; PHOSPHATIDYLCHOLINES; PHOSPHORYLCHOLINE; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN;

MUS;

EID: 73849098309     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.317     Document Type: Article

References (58)

1. Ackerstaff E, Glunde K, Bhujwalla ZM. (2003). Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem 90: 525-533.
2. Al-Saffar NM, Troy H, Ramirez de Molina A, Jackson LE, Madhu B, Griffiths JR et al. (2006). Noninvasive magnetic resonance spectro-scopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res 66: 427-434.
3. Aoyama C, Liao H, Ishidate K. (2004). Structure and function of choline kinase isoforms in mammalian cells. Prog Lipid Res 43: 266-281.
4. Aoyama C, Ohtani A, Ishidate K. (2002). Expression and characterization of the active molecular forms of choline/ethanolamine kinase-alpha and-beta in mouse tissues, including carbon tetra-chloride-induced liver. Biochem J 363: 777-784.
5. Avruch J, Khokhlatchev A, Kyriakis JM, Luo Z, Tzivion G, Vavvas D et al. (2001). Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 56: 127-155.
6. Banez-Coronel M, de Molina AR, Rodriguez-Gonzalez A, Sarmentero J, Ramos MA, Garcia-Cabezas MA et al (2008). Choline kinase alpha depletion selectively kills tumoral cells. Curr Cancer Drug Targets 8: 709-719.
7. Bos JL. (1989). ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689.
8. Buchanan FG, McReynolds M, Couvillon A, Kam Y, Holla VR, Dubois RN et al. (2005). Requirement of phospholipase D1 activity in H-RasV12-induced transformation. Proc Natl Acad Sci USA 102: 1638-1642.
9. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A et al. (2008). Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074.
10. de Molina AR, Banez-Coronel M, Gutierrez R, Rodriguez-Gonzalez A, Olmeda D, Megias D et al (2004). Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res 64: 6732-6739.
11. Degani H, Horowitz A, Itzchak Y. (1986). Breast tumors: evaluation with P-31 MR spectroscopy. Radiology 161: 53-55.
12. Eliyahu G, Kreizman T, Degani H. (2007). Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer 120: 1721-1730.
13. Exton JH. (1990). Signaling through phosphatidylcholine breakdown. J Biol Chem 265: 1-4.
14. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. (2001). Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 294: 1942-1945.
15. Foster DA, Xu L. (2003). Phospholipase D in cell proliferation and cancer. Mol Cancer Res 1: 789-800.
16. Glunde K, Bhujwalla ZM. (2007). Choline kinase alpha in cancer prognosis and treatment. Lancet Oncol 8: 855-857.
17. Glunde K, Jacobs MA, Bhujwalla ZM. (2006). Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn 6: 821-829.
18. Glunde K, Raman V, Mori N, Bhujwalla ZM. (2005). RNA interference- mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res 65: 11034-11043.
19. Grant S. (2008). Cotargeting survival signaling pathways in cancer. J Clin Invest 118: 3003-3006.
20. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70.
21. Hancock JF. (2007). PA promoted to manager. Nat Cell Biol 9: 615-617.
22. Hernandez-Alcoceba R, Fernandez F, Lacal JC. (1999). in vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res 59: 3112-3118.
23. Hernandez-Alcoceba R, Saniger L, Campos J, Nunez MC, Khaless F, Gallo MA et al. (1997). Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene 15: 2289-2301.
24. Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S et al. (2008). Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ 15: 80-88.
25. Ihle NT, Powis G. (2009). Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther 8: 1-9.
26. 0Ascenzo S et al. (2005). Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res 65: 9369-9376.
27. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H et al. (2008). Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclini-cal mouse model. J Clin Invest 118: 3051-3064.
28. 0Souza-Schorey C, Barbieri MA, Cooper JA, Stahl PD. (1997). Uncoupling of membrane ruffling and pinocytosis during Ras signal transduction. J Biol Chem 272: 10337-10340.
29. Luo J, Manning BD, Cantley LC. (2003). Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4: 257-262.
30. Malito E, Sekulic N, Too WC, Konrad M, Lavie A. (2006). Elucidation of human choline kinase crystal structures in complex with the products ADP or phosphocholine. J Mol Biol 364: 136-151.
31. Martinelli G, Iacobucci I, Paolini S, Ottaviani E. (2008). Farnesyl-transferase inhibition in hematologic malignancies: the clinical experience with tipifarnib. Clin Adv Hematol Oncol 6: 303-310.
32. Mazie AR, Spix JK, Block ER, Achebe HB, Klarlund JK. (2006). Epithelial cell motility is triggered by activation of the EGF receptor through phosphatidic acid signaling. J Cell Sci 119: 1645-1654.
33. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE et al. (2006). Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249-279.
34. McCubrey JA, Steelman LS, Franklin RA, Abrams SL, Chappell WH, Wong EW et al. (2007). Targeting the RAF/MEK/ERK, PI3K/ AKT and p53 pathways in hematopoietic drug resistance. Adv Enzyme Regul 47: 64-103.
35. Nozawa S, Ohno T, Banno Y, Dohjima T, Wakahara K, Fan DG et al. (2005). Inhibition of platelet-derived growth factor-induced cell growth signaling by a short interfering RNA for EWS-Fli1 via down-regulation of phospholipase D2 in Ewing sarcoma cells. J Biol Chem 280: 27544-27551.
36. Omerovic J, Hammond DE, Clague MJ, Prior IA. (2008). Ras isoform abundance and signalling in human cancer cell lines. Oncogene 27: 2754-2762.
37. Onodera K, Okubo A, Yasumoto K, Suzuki T, Kimura G, Nomoto K. (1986). 31P nuclear magnetic resonance analysis of lung cancer: the perchloric acid extract spectrum. Jpn J Cancer Res 77: 1201-1206.
38. Pal SK, Figlin RA, Reckamp KL. (2008). The role of targeting mammalian target of rapamycin in lung cancer. Clin Lung Cancer 9: 340-345.
39. Ramirez de Molina A, Gallego-Ortega D, Sarmentero J, Banez-Coronel M, Martin-Cantalejo Y, Lacal JC. (2005). Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis. Cancer Res 65: 5647-5653.
40. Ramirez de Molina A, Penalva V, Lucas L, Lacal JC. (2002a). Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene 21: 937-946.
41. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez J, Bonilla F et al. (2002b). Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 296: 580-583.
42. Ramirez de Molina A, Rodriguez-Gonzalez A, Lacal JC. (2004). From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design. Cancer Lett 206: 137-148.
43. Ramirez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Taron M, Ramirez de Molina V, Cejas P et al. (2007). Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol 8: 889-897.
44. Rizzo M, Romero G. (2002). Pharmacological importance of phospholipase D and phosphatidic acid in the regulation of the mitogen-activated protein kinase cascade. Pharmacol Ther 94: 35-50.
45. Rizzo MA, Shome K, Vasudevan C, Stolz DB, Sung TC, Frohman MA et al. (1999). Phospholipase D and its product, phosphatidic acid, mediate agonist-dependent raf-1 translocation to the plasma membrane and the activation of the mitogen-activated protein kinase pathway. J Biol Chem 274: 1131-1139.
46. Rizzo MA, Shome K, Watkins SC, Romero G. (2000). The recruitment of Raf-1 to membranes is mediated by direct interaction with phosphatidic acid and is independent of association with Ras. J Biol Chem 275: 23911-23918.
47. Rodriguez-Gonzalez A, de Molina AR, Fernandez F, Ramos MA, Nunez Mdel C, Campos J et al. (2003a). Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene 22: 8803-8812.
48. Rodriguez-Gonzalez A, Ramirez de Molina A, Fernandez F, Ramos MA, del Carmen Nunez M, Campos J et al. (2003b). Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene 22: 8803-8812.
49. Sebolt-Leopold JS, Herrera R. (2004). Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4: 937-947.
50. Soejima K, Fang W, Rollins BJ. (2003). DNA methyltransferase 3b contributes to oncogenic transformation induced by SV40T antigen and activated Ras. Oncogene 22: 4723-4733.
51. Telang S, Lane AN, Nelson KK, Arumugam S, Chesney J. (2007). The oncoprotein H-RasV12 increases mitochondrial metabolism. Mol Cancer 6: 77.
52. Telang S, Yalcin A, Clem AL, Bucala R, Lane AN, Eaton JW et al. (2006). Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene 25: 7225-7234.
53. Thornburg JM, Nelson KK, Clem BF, Lane AN, Arumugam S, Simmons A et al. (2008). Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res 10: R84.
54. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. (2009). Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid\-competition with rapamycin. Mol Cell Biol 29: 1411-1420.
55. Vieira AV, Lamaze C, Schmid SL. (1996). Control of EGF receptor signaling by clathrin-mediated endocytosis. Science 274: 2086-2089.
56. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. (2008). Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140.
57. Yuan TL, Cantley LC. (2008). PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497-5510.
58. Zhao C, Du G, Skowronek K, Frohman MA, Bar-Sagi D. (2007). Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to Ras activation by Sos. Nat Cell Biol 9: 706-712.